Successful Reduced-intensity Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome with Severe Coronary Artery Disease

Overview

Journal Int J Hematol

Specialty Hematology

Date 2006 Mar 4

PMID 16513535

Authors

Shigeki Kosugi

Makoto Hirokawa

Yoshinari Kawabata

Hitoshi Hasegawa

Tomoko Yoshioka

Ikuo Miura

Ken-Ichi Sawada

Affiliations

Soon will be listed here.

Abstract

A 60-year-old Japanese man with myelodysplastic syndrome (MDS) and effort angina was referred to our clinic for treatment of MDS. The patient was transfusion-dependent and displayed coronary artery disease (CAD) with 99% obstruction of the left anterior descending coronary artery. Treatment comprised reduced-intensity hematopoietic stem cell transplantation with administration of fludarabine phosphate (180 mg/m(2)) and busulfan (8 mg/kg), followed by allogeneic peripheral blood stem cell transplantation from an HLA-matched sister. The regimen was well tolerated, and engraftment occurred rapidly without any therapy-related complications, including cardiovascular attack. Sex chromosome analysis by fluorescence in situ hybridization revealed complete donor chimerism on day 29 for bone marrow cells and on day 59 for peripheral blood leukocytes. The patient became transfusion-independent on posttransplantation day 8. As of 22 months postoperatively, he remains well, with 100% Karnofsky performance status, a limited type of chronic graft-versus-host disease, and no recurrence of disease. The clinical course of the patient suggests that this preparative regimen allows safe allogeneic stem cell transplantation for MDS patients with severe CAD.

References

Goldberg S, Klumpp T, Magdalinski A, Mangan K . Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998; 16(12):3796-802. DOI: 10.1200/JCO.1998.16.12.3796. View

Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D . Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120(2):187-200. DOI: 10.1046/j.1365-2141.2003.03907.x. View

Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y . Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003; 102(12):4236-42. DOI: 10.1182/blood-2002-10-3289. View

Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Goller V, Clausen M . Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol. 1994; 12(5):998-1004. DOI: 10.1200/JCO.1994.12.5.998. View

Ghobrial I, Bunch T, Caplice N, Edwards W, Miller D, Litzow M . Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc. 2004; 79(3):403-6. DOI: 10.4065/79.3.403. View

Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P . Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997; 89(12):4531-6. View

Arruda J, Costa M, Brito Jr F, Tedesco H, Barbosa A, Ribeiro E . Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol. 2003; 91(11):1363-5. DOI: 10.1016/s0002-9149(03)00333-3. View

Eagle K, Berger P, Calkins H, Chaitman B, Ewy G, Fleischmann K . ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996.... Circulation. 2002; 105(10):1257-67. View

Luger S, Sacks N . Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?. Bone Marrow Transplant. 2002; 30(4):199-206. DOI: 10.1038/sj.bmt.1703610. View

10.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343(11):750-8. DOI: 10.1056/NEJM200009143431101. View

11.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-99. View

12.

Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G . American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999; 17(10):3333-55. DOI: 10.1200/JCO.1999.17.10.3333. View

13.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

14.

Stamm C, Westphal B, Kleine H, Petzsch M, Kittner C, Klinge H . Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003; 361(9351):45-6. DOI: 10.1016/S0140-6736(03)12110-1. View

15.

Wang F, Trester C . Bone marrow cells and myocardial regeneration. Int J Hematol. 2004; 79(4):322-7. DOI: 10.1532/ijh97.03091. View

16.

Khouri I, Keating M, Korbling M, Przepiorka D, Anderlini P, OBrien S . Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998; 16(8):2817-24. DOI: 10.1200/JCO.1998.16.8.2817. View

17.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View

18.

Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G, Emdin M . Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004; 34(10):877-81. DOI: 10.1038/sj.bmt.1704656. View